Previous 10 | Next 10 |
2024-01-11 07:53:52 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy Aclaris posts topline data from mid-stage trial for eczema therapy ...
2024-01-10 15:09:26 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris posts topline data from mid-stage trial for eczema therapy Aclaris to slash 46% of workforce as it reprioritizes drug programs Se...
2024-01-10 10:00:10 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and utilities could perform better in 2024 - analyst For further details see: See...
2024-01-10 07:53:46 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris to slash 46% of workforce as it reprioritizes drug programs Aclaris Therapeutics announces patent license agreement with Sun Pharma for a...
- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) --...
2023-12-20 10:00:08 ET More on Health Care Select Sector SPDR XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble For further details see: ...
2023-12-19 17:07:01 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics announces patent license agreement with Sun Pharma ...
- ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS),...
2023-12-18 15:30:01 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for ACRS on December 18, 2023 04:01PM ET. The previous analyst recommendation was Underperform. ACRS was trading at $0.9377 at issue of the analyst recommendation. The overall analyst conse...
2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
BioCryst Pharmaceuticals (NASDAQ: BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. T...
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on ...
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on...